AZ doses first participants with COVID-19 variant vaccine

AstraZeneca (AZ) has announced that the first participants have been vaccinated as part of a Phase II/III trial testing a new COVID-19 variant vaccine – AZD2816. The trial, which is set to recruit approximately 2,250 participants, will administer AZD2816 to individuals who have been previously vaccinated with AZ’s authorised COVID-19 vaccine Vaxzevria or an mRNA vaccine, at least three months after their last dose.